CA3185253A1 - Anti-surrogate light chain antibodies - Google Patents

Anti-surrogate light chain antibodies

Info

Publication number
CA3185253A1
CA3185253A1 CA3185253A CA3185253A CA3185253A1 CA 3185253 A1 CA3185253 A1 CA 3185253A1 CA 3185253 A CA3185253 A CA 3185253A CA 3185253 A CA3185253 A CA 3185253A CA 3185253 A1 CA3185253 A1 CA 3185253A1
Authority
CA
Canada
Prior art keywords
antibody
sequence
human
light chain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3185253A
Other languages
English (en)
French (fr)
Inventor
Lawrence Horowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Health Care D/b/a Children's Minnesota
Original Assignee
Children's Health Care D/b/a Children's Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Health Care D/b/a Children's Minnesota filed Critical Children's Health Care D/b/a Children's Minnesota
Publication of CA3185253A1 publication Critical patent/CA3185253A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3185253A 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies Pending CA3185253A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562111018P 2015-02-02 2015-02-02
US62/111,018 2015-02-02
CA2975346A CA2975346A1 (en) 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2975346A Division CA2975346A1 (en) 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies

Publications (1)

Publication Number Publication Date
CA3185253A1 true CA3185253A1 (en) 2016-08-11

Family

ID=56564528

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3185253A Pending CA3185253A1 (en) 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies
CA2975346A Pending CA2975346A1 (en) 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2975346A Pending CA2975346A1 (en) 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies

Country Status (10)

Country Link
US (1) US10858448B2 (https=)
EP (2) EP3253793A4 (https=)
JP (1) JP2018507254A (https=)
KR (1) KR102590740B1 (https=)
CN (1) CN107849123A (https=)
AU (1) AU2016215676B2 (https=)
CA (2) CA3185253A1 (https=)
HK (1) HK1247941A1 (https=)
IL (1) IL253579A0 (https=)
WO (1) WO2016126488A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016126488A1 (en) 2015-02-02 2016-08-11 Sea Lane Biotechnologies, Llc Anti-surrogate light chain antibodies
HK1250146A1 (zh) 2015-02-05 2018-11-30 Stc.Unm 抗前-bcr拮抗剂和方法
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CA3128502A1 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
US12134655B2 (en) * 2019-04-30 2024-11-05 Absci Corporation Cancer associated antibody compositions and methods of use
CN112300282A (zh) * 2020-11-03 2021-02-02 南京北恒生物科技有限公司 靶向cd7的人源化抗体及其用途
US12285494B2 (en) 2021-02-16 2025-04-29 Children's Health Care Methods for treating B-ALL by administering a pre-BCR complex antagonist
WO2024077104A2 (en) * 2022-10-04 2024-04-11 Mink Therapeutics, Inc. Fibroblast activation protein (fap) car-invariant natural killer t cells and uses thereof
WO2025212740A1 (en) * 2024-04-03 2025-10-09 Mink Therapeutics, Inc. Composition and methods for treating colorectal cancer liver metastasis (crc liver mets)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US62950A (en) 1867-03-19 Improvement in apparatus foe the manufacture of vinegar
US2010A (en) 1841-03-18 Machine foe
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
EP0269127B1 (en) 1986-11-27 1994-02-23 F. Hoffmann-La Roche Ag Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US5182205A (en) 1986-11-27 1993-01-26 Hoffmann-La Roche Inc. Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6326155B1 (en) 1995-03-20 2001-12-04 Dyax Corp. Engineering affinity ligands for macromolecules
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
WO1999006541A1 (fr) * 1997-07-29 1999-02-11 Sumitomo Electric Industries, Ltd. Anticorps du recepteur des cellules pre-b non humaines
JPH11133028A (ja) * 1997-10-29 1999-05-21 Sumitomo Electric Ind Ltd 抗ヒトプレｂ細胞レセプター抗体
US20030215453A1 (en) * 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
GB2377997A (en) * 2001-07-24 2003-01-29 Bookham Technology Plc Connection of a non-perpendicular optical fibre to an optical device
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
EP2069558B1 (en) 2006-10-02 2013-05-01 Sea Lane Biotechnologies,llc. Design and construction of diverse synthetic peptide and polypeptide libraries
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
WO2010006286A2 (en) 2008-07-11 2010-01-14 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate kappa light chain sequences
KR101829073B1 (ko) * 2009-06-26 2018-02-13 아이2 파마슈티컬스, 인크. 대리 경쇄의 발현
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
WO2016126488A1 (en) 2015-02-02 2016-08-11 Sea Lane Biotechnologies, Llc Anti-surrogate light chain antibodies
HK1250146A1 (zh) * 2015-02-05 2018-11-30 Stc.Unm 抗前-bcr拮抗剂和方法

Also Published As

Publication number Publication date
EP3253793A4 (en) 2018-11-14
HK1247941A1 (zh) 2018-10-05
IL253579A0 (en) 2017-09-28
CA2975346A1 (en) 2016-08-11
WO2016126488A1 (en) 2016-08-11
EP4177267A1 (en) 2023-05-10
AU2016215676B2 (en) 2021-12-02
JP2018507254A (ja) 2018-03-15
AU2016215676A1 (en) 2017-08-10
US20180265594A1 (en) 2018-09-20
EP3253793A1 (en) 2017-12-13
KR20170120120A (ko) 2017-10-30
KR102590740B1 (ko) 2023-10-18
CN107849123A (zh) 2018-03-27
US10858448B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
AU2016215676B2 (en) Anti-surrogate light chain antibodies
EP2528948B1 (en) Novel lowered affinity antibodies and methods of making the same
EP2989204B1 (en) Isolation of therapeutic target specific vnar domains to icosl
JP7663977B2 (ja) 抗ｐｄ―ｌ１抗体およびその用途
JP2024009808A (ja) Ｉｌｔ７結合分子及びその使用方法
US20190031770A1 (en) Intercalated single-chain variable fragments
WO2009142460A2 (en) Antibody-peptide fused synergibody
KR20110028543A (ko) 항체 대용물 카파 경쇄 서열을 포함하는 구축물 및 라이브러리
CA2685213A1 (en) Engineered rabbit antibody variable domains and uses thereof
US20100233167A1 (en) Chain reaction creating oligomers from repeat units of binding molecules
HK40090806A (en) Anti-surrogate light chain antibodies
US20110245100A1 (en) Generation of antibodies to an epitope of interest
WO2025228315A1 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
Rouet Mutational, structural and evolutionary analyses of the human antibody VL domain
HK1183309B (en) Novel lowered affinity antibodies and methods of making the same
HK1159132A (en) Constructs and libraries comprising antibody surrogate kappa light chain sequences
HK1183309A (en) Novel lowered affinity antibodies and methods of making the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230227

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240905

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240930

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241028

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250609

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250609

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260218